Literature DB >> 11879376

Levetiracetam psychosis in children with epilepsy.

E H Kossoff1, G K Bergey, J M Freeman, E P Vining.   

Abstract

PURPOSE: Levetiracetam is a new anticonvulsant (AED) with a novel mechanism of action. Although it is generally well tolerated with a good cognitive profile, irritability and hostility have been reported in some adults taking levetiracetam. Observations in children are limited; levetiracetam is not yet approved by the Food and Drug Administration for use in children.
METHODS: In four young patients, acute psychosis developed within days to months of initiation of levetiracetam for seizures.
RESULTS: A 5-year-old girl began having visual hallucinations of spiders in her room 14 days after starting levetiracetam. A 13-year-old boy began having auditory hallucinations, insomnia, and screaming behavior 3 months after initiation of levetiracetam. A 16-year-old girl became acutely agitated, hyperreligious, and had persecutory delusions within 7 days of starting levetiracetam. A 17-year-old girl had auditory hallucinations telling her to sing and yell after 30 days of taking the drug. All four children had dramatic improvement within days of either discontinuing or decreasing the dose of levetiracetam. The three adolescents had historical findings consistent with mild behavioral problems before initiating levetiracetam, and all four patients had prior cognitive deficits.
CONCLUSIONS: Reversible treatment-emergent psychosis associated with levetiracetam therapy was observed in four children and adolescents. Whether rapid initiation or prior neurobehavioral problems predispose to this side effect is not established.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11879376     DOI: 10.1046/j.1528-1157.2001.32101.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  33 in total

Review 1.  New drugs for the treatment of epilepsy: a practical approach.

Authors:  S Beyenburg; J Bauer; M Reuber
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

2.  Much ado about something or nothing: behavioral problems with levetiracetam use in epilepsy patients.

Authors:  Patricia E Penovich
Journal:  Epilepsy Curr       Date:  2004 Jul-Aug       Impact factor: 7.500

Review 3.  Neuropsychological and behavioral effects of antiepilepsy drugs.

Authors:  David W Loring; Susan Marino; Kimford J Meador
Journal:  Neuropsychol Rev       Date:  2007-10-18       Impact factor: 7.444

4.  A new generation of anticonvulsants for the treatment of epilepsy in children.

Authors:  O Carter Snead; Elizabeth J Donner
Journal:  Paediatr Child Health       Date:  2007-11       Impact factor: 2.253

Review 5.  Levetiracetam in childhood epilepsy.

Authors:  Alberto Verrotti; Ebe D'Adamo; Pasquale Parisi; Francesco Chiarelli; Paolo Curatolo
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 6.  Newer antiepileptic drugs: evidence based use.

Authors:  Gouri Rao Passi
Journal:  Indian J Pediatr       Date:  2014-06-25       Impact factor: 1.967

Review 7.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

8.  Levetiracetam as an alternative therapy for Tourette syndrome.

Authors:  M A Martínez-Granero; A García-Pérez; F Montañes
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

Review 9.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 10.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.